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Abstract: Multidrug resistance (MDR) is the main obstacle to current chemotherapy and it is mainly
due to the overexpression of some efflux transporters such as MRP1. One of the most studied strategies
to overcome MDR has been the inhibition of MDR pumps through small molecules, but its translation
into the clinic unfortunately failed. Recently, a phenomenon called collateral sensitivity (CS) emerged
as a new strategy to hamper MDR acting as a synthetic lethality, where the genetic changes developed
upon the acquisition of resistance towards a specific agent are followed by the development of
hypersensitivity towards a second agent. Among our library of sigma ligands acting as MDR
modulators, we identified three compounds, F397, F400, and F421, acting as CS-promoting agents.
We deepened their CS mechanisms in the “pure” model of MRP1-expressing cells (MDCK-MRP1) and
in MRP1-expressing/drug resistant non-small cell lung cancer cells (A549/DX). The in vitro results
demonstrated that (i) the three ligands are highly cytotoxic for MRP1-expressing cells; (ii) their
effect is MRP1-mediated; (iii) they increase the cytotoxicity induced by cis-Pt, the therapeutic agent
commonly used in the treatment of lung tumors; and (iv) their effect is ROS-mediated. Moreover, a
preclinical in vivo study performed in lung tumor xenografts confirms the in vitro findings, making
the three CS-promoting agents candidates for a novel therapeutic approach in lung resistant tumors.
Keywords: collateral sensitivity; MDR; MRP1; resistant tumors; lung tumors; ROS
1. Introduction
Drug resistance, either acquired or intrinsic, is the major hurdle in treating cancer by chemotherapy.
The simultaneous resistance to structurally unrelated drugs, also named multidrug resistance (MDR),
often results from the overexpression of some drug efflux pumps in the cell membrane that reduce
the intracellular drug levels to less than therapeutic concentrations [1–8]. In particular, three proteins
belonging to the ATP-binding cassette (ABC) transporter superfamily have been identified as involved
in MDR: P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated Protein 1 (MRP1/ABCC1),
and breast cancer resistance protein (BCRP/ABCG2).
During recent decades, several strategies to overcome MDR in cancer have been described. One
of the most studied strategies was focused on the inhibition of the pumps through small molecules;
inhibitors of MDR pumps, devoid of intrinsic toxicity, upon co-administration with the cytotoxic drugs
would hamper the drug efflux and reverse resistance [9–11]. However, translation into the clinic of
this approach has failed so far. One of the lately proposed approaches is related to a phenomenon
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called collateral sensitivity (CS): some compounds are able to selectively kill MDR cells but not the
drug-sensitive parental cells from which they are derived [12–16]. The term CS was firstly described
by Szybalski and Bryson in 1952 after the observations that drug-resistant Escherichia coli displayed
hypersensitivity to unrelated drugs, thus acquiring a potentially exploitable weakness as a result of
the drug selection process [13]. In 1985, the same phenomenon was observed for cells overexpressing
P-gp. CS is not yet fully understood and four main hypotheses have been proposed as the inducing
mechanisms in MDR cells: (1) increase of reactive oxygen species (ROS) through the induction of futile
hydrolysis of ATP; (2) increased sensitivity to changes in energy levels; (3) extrusion of endogenous
substrates essential for cell survival; and (4) membrane perturbation [14].
CS can be quantitatively assessed in vitro by determining the selectivity ratio (SR), that is, the
ratio between the cytotoxicity of a compound against the parental cell line and its cytotoxicity against
the MDR-derived line (SR = EC50 parental cells/EC50 MDR cells) [14]. When the SR >1, the compound
displays higher cytotoxicity against the MDR-derived line than its parental cell counterpart, thus
eliciting CS. Conversely, a SR < 1 indicates a resistance of the MDR line towards the compound,
likely because the compound is an ABC transporters substrate. When the SR >2, the compound is
addressed as a CS-promoting agent [12]. The therapeutic approach based on the CS of cancer cells
overexpressing the ABC transporters is substantially different from the strategy of transporter inhibition.
The co-administration of an ABC transporters inhibitor with a cytotoxic drug would re-sensitize the
MDR cells of the drug to the same level as the cells without a transporter expression. By contrast,
treatment with a CS agent results in a more potent action in the MDR cells than in the non-MDR
counterparts. The non-MDR cells could then be re-sensitized to the “traditional” cytotoxic drug. CS
can be considered as a type of synthetic lethality, where the genetic changes developed upon the
acquisition of resistance towards a specific agent are followed by the development of hypersensitivity
towards a second agent [14].
Therefore, CS-promoting agents may be used as single agents for MDR tumor treatments, as
well as agents re-sensitizing MDR tumors to the commonly employed drugs, killing selectively ABC
transporters-expressing cells and/or reducing ABC transporters’ expressions/activity in resistant tumors.
While research of CS agents has been mostly directed among P-gp substrates, whose CS may be
determined by an ROS increase due to the ATP consumption responsible for the drug efflux, verapamil
(L-type calcium channel antagonist, commonly used for the clinical treatment of hypertension) was
found to be a CS agent also in MRP1-expressing cells, exploiting the MRP1 ability to efflux glutathione
(GSH) [17]. GSH sustains the intracellular redox status, acting as a redox regulator, cofactor, substrate,
and antioxidant [14,18–24]. The increase in GSH efflux leads to a dysregulation of the redox state of
cells with a deep impact on cells’ viability.
Therefore, the modulation of intracellular GSH levels through MRP1 can be a powerful approach
in cancer therapy mediated by a sensitizer. In fact, verapamil, after binding to MRP1, is not transported
by this pump, but stimulates the MRP1-mediated GSH efflux [20]. The fast and huge GSH extrusion
triggers a selective apoptosis of cells overexpressing MRP1, as evidenced by treating MRP1-transfected
baby hamster kidney 21 (BHK-21) cells and their parental counterparts (BHK-21) in the same conditions,
thus confirming the need of MRP1 in this phenomenon [25–27].
Nevertheless, very few of the studies focused on CS in MRP1-expressing cells compared with the
experimental works focused on CS in P-gp-expressing cells [16,28–30]. Due to the impact of MRP1
overexpression in cancer development and drug resistance, and the increasing evidence of its role
in CS [19,22,31,32], the aim of the study is the identification of new CS-promoting agents having as
the target the MDR protein MRP1. With this in mind, we had to identify proper MRP1 inhibitors,
first. Although a number of MRP1 inhibitors have been produced during the past 20 years, they
are rarely specific [19,22]. Therefore, we gathered inspiration from our library of sigma-2 receptors’
ligands, that have been recently associated with CS [28,29,33,34]. Sigma-2 receptors, lately identified
as TMEM97 proteins, are overexpressed in diverse types of cancers and their modulation leads to cell
death upon the activation of a number of still investigated pathways [35–45]. Several sigma-2 receptor
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high-affinity ligands have been developed during recent decades (and lately reviewed), revealing
cytotoxic activity through pathways that appear to be molecule-dependent and cell-type-dependent,
with mechanisms that span from caspase-dependent apoptosis, autophagy, increase in ROS, and
mithocondrial superoxide production [36,37,40,44]. Some sigma-2 ligands were surprisingly found
to be able to kill doxorubicin-resistant cells more than the non-resistant counterparts (breast cancer
cells MCF7/DX over MCF7 cells, non-small cell lung cancer A549/DX over A549 cells, colon cancer
HT29/DX over HT29 cells) [28,29,33]. The investigation of this property led to find that these
compounds were also P-gp substrates and the activation of a futile ATP cycle with an increase in ROS
production could be responsible for their CS properties. Herein, we investigated the interaction of
these compounds with MRP1 pumps in order to identify novel MRP1 modulators to be exploited as CS
agents. Three compounds, derived from three different classes of sigma-2 receptor ligands (Figure 1:
F397, 6,7-dimethoxy-2-{4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl}-1,2,3,4-tetrahydroisoquinoline [28];
F421 (N-{4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl}-3,4-dimethoxybenzylamine [41]; and F400 6,7-dime
thoxy-2-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propionyl]-1,2,3,4 tetrahydroisoquinoline) [42]
emerged as MRP1 modulators in the preliminary screening and for this reason they were further
evaluated in the appropriate MDR cell line models and in a preclinical in vivo model.
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The activity at the MRP1 pump was determined measuring the transport inhibition of the pro-
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MRP1) by the in vitro biological assay usually performed to study an MRP1 interaction. As depicted 
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tetralin series (obtained from SAfiR studies on the sigma-2 reference compound PB28 [42]), emerged 
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2. Results and Discu sion
2.1. MRP1 Activity and Antiproliferative Activity in - T and MDCK-MRP1: Determination of the
Selectivity Ratio (SR)
Within t e search for novel CS agents acting 1 proteins, the compounds selected among
the different series of sigma-2 ligands were investigated for their activity at MRP1, paralleled with their
cytotoxicity in the parental Madin–Darby canine kidney (MDCK-wt) cells and in the MDR-derived cells
(MDCK-MRP1) for the determination of their SR (EC50 parental cells/EC50 MDR cells). The activity
at the MRP1 pump was determined measuring the transport inhibition of the pro-fluorescent probe
Calcein-AM, an MRP1 substrate, in the MRP1-overexpressing cell line (MDCK-MRP1) by the in vitro
biological assay usually performed to study an MRP1 interaction. As depicted in Table 1, compounds
F397 and F421, bearing the 1-(4-fluorophenyl)indol-3-yl moiety, as in the sigma-2 reference c mpound
siramesine [43,44], together with compo nd F400, belonging to the tetralin series (obtained from SAfiR
studies on the sigma-2 reference compound PB28 [42]), emerged as the most promising CS agents
among the tested ligands with an SR > 2. In detail, as reported in Table 1, the three compounds F397,
F400 and F421 showed a moderate activity vs. MRP1 (EC50 = 16.7, 17.6, and 28 µM, respectively)
performed in the MDCK-MRP1 cells but a high collateral sensitivity action displaying an SR = 3.41,
5.91, and 2.47, respectively. The observed CS effect seems due, considering the inhibition of calcein
transport activity, to the interaction of the three ligands with MRP1. Moreover, these values are
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comparable to those observed for the CS reference compound verapamil (SR = 4.7). All the other
compounds, belonging to our library of sigma-2 ligands, even if displaying a higher MRP1 activity, did
not exert CS-action, as they displayed an SR ≤ 1 (data not shown), similarly to the sigma-2 reference
compound siramesine (SR = 0.56). The SR was measured as the EC50 of the MDCK cells/EC50 of the
MDCK-MRP1 cells.
Table 1. MRP1 activity and collateral sensitivity activity (selectivity ratio, SR) of the three compounds
F397, F400, and F421, and the two reference compounds verapamil and siramesine.
Compound MRP1, EC50 ± SEM, µM SR
F397 16.7 ± 3.2 3.41
F400 17.6 ± 3.8 5.91
F421 28 ± 4.8 2.47
Verapamil 7.9 ± 1.7 4.7
Siramesine 23.2 ± 4.5 0.56
2.2. Collatateral Sensitivity Study
In order to confirm the entity of the three compounds F397, F421, and F400 as sensitizers towards
MRP1, further experiments were conducted on cancer cell lines that endogenously express this efflux
pump. Thus, observing the results drawn from different studies regarding the MRP1 expression in
several solid tumors, we screened the pump’s expression in a variety of cancer cell lines such as the
human colon cancer HT29 cell line and the multidrug-resistant counterpart HT29/DX, human non-small
cell lung cancer A549 cell line and the multidrug-resistant counterpart A549/DX, and four different
types of human breast cancer cell lines: MCF7, SKBR3, T74D, and MDA-MB-231. The immunoblotting
study revealed a high amount of MRP1 in both the multidrug-resistant lung and colon cancer cell lines
with the highest prevalence in A549/DX, followed by the respective parental cell lines A549 and HT29,
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Figure 2. MRP1 expression checked by Western blotting in different cancer cell lines: A549/DX > 
HT29/DX > A549 > HT29 = MDA-MB-231 > MCF7 = SKBR3 = T74D (A): Histogram depicting 
GSH/GSSG basal levels: A549/DX > HT29/DX > A549 > HT29 = MDA-MB-231 > MCF7 = SKBR3 = T74D 
(n = 3/cell line). Relative quantitations are reported below the immunoblot. (B): One-way analysis of 
variance (ANOVA) analysis: **** p < 0.0001 for HT29/DX vs. control HT29, and A549/DX vs. A549. 
Therefore, A549/DX cells were selected as a model to investigate the CS properties of our 
compounds. Firstly, in order to confirm the data observed on the “pure” model MDCK-MRP1, we 
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cytotoxicity as performed in the “pure” MRP1 model. Indeed, the accurate detection of cell viability 
in A549 cells was critical in calculating the SR in a reliable manner. The following experiments, all 
performed in A549/DX cells, were performed after 72 h, i.e., the best timing to detect a cytotoxic effect 
on the slowly growing resistant population. 
First, we wondered if there was a correlation between the inhibition of the MRP1 protein and 
the CS properties of the compounds. To this aim, we adopted a concentration similar to their EC50, 
i.e., 10 µM. In this experimental condition, the three compounds resulted as cytotoxic, confirming 
their behavior as CS-promoting agents in A549/DX cells (Figure 3).  
In order to confirm that the observed effect is due to the interaction of the ligands with MRP1, 
the cellular viability at 72 h has been measured, testing the three ligands in co-administration with 
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Nevertheless, the involvement of a sigma-2 receptor-mediated effect was ruled out by the detection 
of a low density of sigma-2 receptors in A549 cells (data not shown). Additionally, besides the 
reversal of the activity of these ligands by the MRP1 inhibitor MK571, worthy of note is the result 
which was obtained with the three sensitizers in the MCF7 cell line, having a high level of sigma-2 
and low level of MRP1 (as depicted in Figure 1A). While F400 and F421 were not cytotoxic in these 
cells (EC50 > 100 M, data not shown), F397 showed an EC50 = 17.8 M [28]. Importantly, cytotoxic 
activity of F397, which was shown to be a potent P-gp inhibitor in the MCF7 cell line (EC50 = 0.21 M), 
was lower in the corresponding resistant MCF7/DX overexpressing P-gp (EC50 = 21.8 M) [28]. These 
data strongly support the MRP1-mediated CS action of F397 (results from A549 and MDCK cells and 
Figure 2. MRP1 expression checked by estern blotting in different cancer cell lines: A549/DX
> HT29/DX > A549 > HT29 = MDA-MB-231 > MCF7 = SKBR3 = T74D (A): Histogram depicting
GSH/GSSG basal levels: A549/DX > HT29/DX > A549 > HT29 = MDA-MB-231 > MCF7 = SKBR3 =
T74D (n = 3/cell line). Relative quantitations are reported below the immunoblot. (B): One-way analysis
of variance (ANOVA) analysis: **** p < 0.0001 for HT29/DX vs. control HT29, and A549/DX vs. A549.
Subsequently, taking into consideration the important role that MRP1 plays in glutathione
homeostasis and in the efflux of several chemotherapeutic drugs conjugated with glutathione
(PMID:11902585), the basal levels of GSH/GSSG have been evaluated in these cancer cell lines.
Hence, s depicted in Figure 2B, all cell lines exhibite similar values of the GSH/GSSG ratio, with
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A549/DX displaying the highest GSH/GSSG ratio. This result was not surprising. Indeed, A549 cells are
known for having high levels of GSH, caused mainly by the high levels of anti-oxidant enzymes [46]
that prevent the oxidation of GSH. Moreover, we previously demonstrated that cells with acquired
resistance to doxorubicin increase the metabolic flux through the pentose phosphate pathways (PPP)
that produce NADPH, a critical metabolite to regenerate the reduced form of glutathione. This
phenotype is peculiar for drug-resistant MRP1-expressing cells [47], as A549/DX are. The high levels of
GSH may protect cells from the oxidative damage induced by cis-Pt [48] and activate the glutathione
S-transferase (GST) enzymes that conjugate GSH to cis-Pt and promote its efflux via MRP1 [49].
Therefore, A549/DX cells were selected as a model to investigate the CS properties of our
compounds. Firstly, in order to confirm the data observed on the “pure” model MDCK-MRP1,
we tested, in the same experimental conditions, the SR of F397, F400, and F421 by measuring their
cytotoxicity in the resistant A549/DX cells and their parental counterpart A549, obtaining an SR ≥ 2 for
all (SR = 2.5 for derivative F397, SR = 2.1 for F400, and SR = 2 for F421).
Since the doubling time of A549 cells is 22 h and the doubling time of A549/DX cells is 61 h
(data not shown), in this first experimental set we used a 24 h time, i.e., the most suitable for A549 cells’
cytotoxicity as performed in the “pure” MRP1 model. Indeed, the accurate detection of cell viability
in A549 cells was critical in calculating the SR in a reliable manner. The following experiments, all
performed in A549/DX cells, were performed after 72 h, i.e., the best timing to detect a cytotoxic effect
on the slowly growing resistant population.
First, we wondered if there was a correlation between the inhibition of the MRP1 protein and
the CS properties of the compounds. To this aim, we adopted a concentration similar to their EC50,
i.e., 10 µM. In this experimental condition, the three compounds resulted as cytotoxic, confirming their
behavior as CS-promoting agents in A549/DX cells (Figure 3).
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Figure 3. Cell viability of F397, F400, and F421 at 10 M alone and with MK571 at 25 M on the 
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We next observed the antiproliferative effect of these three compounds co-administrated with 
the elective drug usually chosen for the treatment of the non-small cell lung cancer, cis-platinum (cis-
Pt). Cis-Pt is effective against cancer cells because it creates cross-links between purine bases, alters 
the double helix conformation, and induces DNA strand breaks, impairing the DNA repairing 
machinery as well. These DNA damages trigger apoptosis in sensitive cells [50]. For this broad 
spectrum of activities, cis-Pt is the first line of treatment in several cancer types, including lung cancer 
[50]. Unfortunately, since cis-Pt is a substrate of MRP1 [1], which effluxes cis-Pt, limiting its 
intracellular accumulation, MRP1-expressing cancer cells are usually resistant to the cytotoxic effect 
of the drug [51,52]. This is the case of A459/DX cells, rich with MRP1, a prototype of lung cancer cells 
resistant to cis-Pt.  
At first, the viability of each compound on A549/DX after 72 h treatment, alone or in combination 
with the MRP1 inhibitor MK571 or the antineoplastic drug cis-Pt both at 25 M has been evaluated. 
The concentration of cis-Pt at 25 M was chosen as A549/DX cells are platinum-resistant [53], but cells 
are re-sensitized when the anticancer drug is co-administered with MK571 at the same concentration. 
As illustrated in Figure 4, MK571 alone was not cytotoxic to A549/DX cells. The sensitivity to cis-Pt 
was restored when co-administrated with MK571, suggesting that MRP1 plays a key role in inducing 
the resistance to cis-Pt in our model.  
Using MK571 as a reference, a comparison was made between the cytotoxic effect of the 
compounds F397, F400, and F421 alone at 10 M and in association with cis-Pt at 25 M (Figure 4). 
All the three compounds have a cytotoxic effect on their own, that drastically increases upon co-
administration with cis-Pt.  
Figure 3. Cell viability of F397, F400, and F421 at 10 µM alone and with MK571 at 25 µM on the
A549/DX cell line. E ch bar represents the mean ± SEM of three experiments performed in triplicate.
One-way analysis of variance (ANOVA) analysis: * p < 0.05; ** p < 0.01; **** p < 0.0001 vs. control.
In order to confirm that the observed effect is due to the interaction of the ligands with MRP1, the
cellular viability at 72 h has been measured, testing the three ligands in co-administration with the
MRP1 inhibitor, MK571, at 25 µM, a concentration that fully inhibited the MRP1 ATPase activity on
A549/DX cells (ATPase activity in untreated A549/DX cells: 4.32 ± 0.58 nmoles Pi/min/mg prot; ATPase
activity in MK571-treated A549/DX cells: 0.40 ± 0.12 nmoles Pi/min/mg prot). As depicted in Figure 3,
the cytotoxicity of the three compounds was reverted by the MRP1 inhibitor MK571, confirming that
MRP1 is the ta get of the F397, F400, and F421 compounds in A549/DX.
Whil F400 is devoid of sigma-2 receptor affinity [42], F421 and F397 respectively display
a moderate (Ki = 169 nM) [41] to a high affinity (Ki = 5.34 nM) [28] towards sigma-2 receptors.
Nevertheless, the involvement of a sigma-2 receptor-mediated effect was ruled out by the detection of
a low density of sigma-2 receptors in A549 cells (data not shown). Additionally, besides the reversal
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of the activity of these ligands by the MRP1 inhibitor MK571, worthy of note is the result which was
obtained with the three sensitizers in the MCF7 cell line, having a high level of sigma-2 and low level of
MRP1 (as depicted in Figure 1). While F400 and F421 were not cytotoxic in these cells (EC50 > 100 µM,
data not shown), F397 showed an EC50 = 17.8 µM [28]. Importantly, cytotoxic activity of F397, which
was shown to be a potent P-gp inhibitor in the MCF7 cell line (EC50 = 0.21 µM), was lower in the
corresponding resistant MCF7/DX overexpressing P-gp (EC50 = 21.8 µM) [28]. These data strongly
support the MRP1-mediated CS action of F397 (results from A549 and MDCK cells and their resistant
counterparts that overexpress MRP1 but not P-gp), that by contrast, is devoid of P-gp-mediated CS
properties (results from MCF7 cells).
We next observed the antiproliferative effect of these three compounds co-administrated with the
elective drug usually chosen for the treatment of the non-small cell lung cancer, cis-platinum (cis-Pt).
Cis-Pt is effective against cancer cells because it creates cross-links between purine bases, alters the
double helix conformation, and induces DNA strand breaks, impairing the DNA repairing machinery as
well. These DNA damages trigger apoptosis in sensitive cells [50]. For this broad spectrum of activities,
cis-Pt is the first line of treatment in several cancer types, including lung cancer [50]. Unfortunately,
since cis-Pt is a substrate of MRP1 [1], which effluxes cis-Pt, limiting its intracellular accumulation,
MRP1-expressing cancer cells are usually resistant to the cytotoxic effect of the drug [51,52]. This is the
case of A459/DX cells, rich with MRP1, a prototype of lung cancer cells resistant to cis-Pt.
At first, the viability of each compound on A549/DX after 72 h treatment, alone or in combination
with the MRP1 inhibitor MK571 or the antineoplastic drug cis-Pt both at 25 µM has been evaluated.
The concentration of cis-Pt at 25 µM was chosen as A549/DX cells are platinum-resistant [53], but cells
are re-sensitized when the anticancer drug is co-administered with MK571 at the same concentration.
As illustrated in Figure 4, MK571 alone was not cytotoxic to A549/DX cells. The sensitivity to cis-Pt
was restored when co-administrated with MK571, suggesting that MRP1 plays a key role in inducing
the resistance to cis-Pt in our model.
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Figure 4. Antiproliferative activity on A549/DX of MK571 and cis-Pt at 25 M alone and in co-
administration; cis-Pt at 25 M and respectively F397, F400, and F421 at 10 M alone and in co-
administration. Each bar represents the mean ± SEM of three experiments performed in triplicate. 
One-way analysis of variance (ANOVA) analysis: **** p < 0.0001 vs. control. 
One of the possible reasons of this sensitization is the ability of these three compounds to inhibit 
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Figure 4. Antiproliferative activity on A549/DX of MK571 and cis-Pt at 25 µM alone and in
co-administration; cis-Pt at 25 µM and respectively F397, F400, and F421 at 10 µM alone and in
co-administration. Each bar represents the mean ± SEM of three experiments performed in triplicate.
One-way analysis of variance (ANOVA) analysis: **** p < 0.0001 vs. control.
Using MK571 as a reference, a comparison was made between the cytotoxic effect of the compounds
F397, F400, and F421 alone at 10 µM and in association with cis-Pt at 25 µM (Figure 4). All the three
compounds have a cytotoxic effect on their own, that drastically increases upon co-administration
with is-Pt.
One of the possible re s ns of this sensitization is the ability of these three compounds to inhibit
the efflux of cis-Pt, which is MRP1-me iated. Interestingly, the cytotoxic effect of the three compounds
combined with cis-Pt was slightly more marked than the effect of MK571 in terms of cell viability.
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This could be associated with a second reason, considering one of the putative mechanisms of CS
consisting of an increased production of ROS, capable of triggering the apoptosis of MDR cells. To
investigate whether this mechanism is involved in the sensitizing effects elicited by F397, F400, and
F421, we measured the intracellular ROS production in A549/DX after 24 h treatment with these
three molecules at 10 µM, with and without 25 µM cis-Pt (Figure 5A). We noticed that these three
compounds alone increased the amount of intracellular ROS. This was further enhanced when they
were co-administrated with the antineoplastic drug, thus allowing its antitumor activity. As reported
in Figure 5B, this effect was reverted by the ROS scavenger Tempol, tested at 10 mM. Moreover, to
verify whether the increase in ROS induced the reduction in cell viability elicited by the compounds,
we evaluated the antiproliferative effect at 72 h of these three sensitizers alone and with 25 µM cis-Pt,
adding 10 mM Tempol at time zero and after 48 h from the incubation. As shown in Figure 5B, the data
obtained are in line with the ROS production hypothesis: higher were the ROS levels, lower was cell
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Figure 5. Intracellular ROS production at 24 h (A) and cell viability at 72 h (B) of compounds F397, 
F400, and F421 alone at 10 M and with 25 M cis-Pt and/or 10 mM Tempol. Each bar represents the 
mean ± SEM of three experiments performed in triplicate. One-way analysis of variance (ANOVA) 
analysis: * p < 0.05; ** p < 0.01; **** p < 0.0001 vs. control. 
Figure 5. Intracellular ROS production at 24 h (A) and cell viability at 72 h (B) of compounds F397,
F400, and F421 alone at 10 µM and with 25 µM cis-Pt and/or 10 mM Tempol. Each bar represents the
mean ± SEM of three experiments performed in triplicate. One-way analysis of variance (ANOVA)
analysis: * p < 0.05; ** p < 0.01; **** p < 0.0001 vs. control.
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An increase in ROS of mitochondrial origin is particularly effective in killing multidrug-resistant
cells [53]. To investigate whether the ROS were of mithocondrial origin, the same experiment was
set up evaluating ROS production at 24 h with Mitotempol, the scavenger of mithocondrial ROS. As
illustrated in Figure 6A, compounds F327, F400, and F421 increased the intramithocondrial ROS. This
effect was enforced by the concurrent administration of cis-Pt, but reversed by Mitotempol. Evaluating
the relative cellular vitality on A549/DX at 72 h, the antiproliferative effect of cis-Pt, negligible when
the drug was used alone, was enhanced by the CS-promoting agents and reverted by Mitotempol



































































































































































































* * * * * * * * * * * *
* * * *
* * * *
























































































































































































* * * * * * * * * * * *
* * * *
* * * *
* * * *
 
(B) 
Figure 6. Mitochondrial ROS production (A) and the relative cellular vitality (B) on A549/DX at 24 h 
using Mitotempol as the scavenger of the mithocondrial ROS in the presence of F397, F400, and F421, 
alone at 10 M, and in the presence of Mitotempol (10 mM) and cis-platinum (25 M). Each bar 
represents the mean ± SEM of three experiments performed in triplicate. One-way analysis of variance 
(ANOVA) analysis: **** p < 0.0001, * p < 0.05 vs. control. 
2.3. In Vivo Tumor Growth  
In order to translate in vivo the capability of F397, F400, and F421 to act as “sensitizers”, A549/DX 
cells were implanted in immune-deficient BALB/C mice, and once the tumor reached the volume of 
50 mm3, the mice were randomized and treated three times weekly with the vehicle (saline solution) 
and/or cis-Pt. As depicted in Figure 7, the tumor volume was monitored daily, confirming the 
resistance of A549/DX against the standard chemotherapy regimen.  
The animals were treated for three times weekly with a single dose of the indole-based ligands 
F397 or F421, while F400 could not be dissolved in solvents suitable for in vivo studies and could not 
Figure 6. Mitochondrial ROS production (A) and the relative cellular vitality (B) on A549/DX at 24 h
using Mitotempol as the scavenger of the mithocondrial ROS in the presence of F397, F400, and F421,
alone at 10 µM, and in the presence of Mitotempol (10 mM) and cis-platinum (25 µM). Each bar
represents the mean ± SEM of three experiments performed in triplicate. One-way analysis of variance
(ANOVA) analysis: **** p < 0.0001, * p < 0.05 vs. control.
2.3. In Vivo Tumor Growth
In order to translate in vivo the capability of F397, F400, and F421 to act as “sensitizers”, A549/DX
cells were implanted in immune-defici nt BALB/C mice, and once h tumor reached the volume of
50 mm3, the mice were randomized and treated three times weekly with the vehicle (saline solution)
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and/or cis-Pt. As depicted in Figure 7, the tumor volume was monitored daily, confirming the resistance
of A549/DX against the standard chemotherapy regimen.
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7. Tumo growth curves: (A) Treatment with saline buffer (ctrl), 397 and F421 at
7.5 nM; (B) administration of 50 mg/Kg cis-Pt alone and with two target compounds F397 or F421;
(C) administrati n of 3 m /Kg MK571, the MRP1 nhibitor, alone and with F397 and F421.
The animals were treated for three times weekly with a single dose of the indole-based ligands
F397 or F421, while F400 could not be dissolved in solvents suitable for in vivo studies and could not be
tested in vivo. The administration of F397 or F421 as single agents determined a low growth reduction
(Figure 7A), but their co-administration with cis-Pt greatly reduced tumor growth (Figure 7B). As for
the in vitro experiments, co-administration of the MRP1 inhibitor MK571 with these sensitizers abated
the cytotoxic effect, supporting that the effect of F397 and F421 is MRP1-mediated (Figure 7C). Of note,
the dose of F397 and F421 effective as an anti-tumor agent in vivo was lower than the dosage effective
as an anti-proliferative agent in vitro. One possible reason could be that part of the anti-tumor effect of
the compounds was mediated by their activity on the tumor microenvironment, not necessarily only
on tumor cells. This aspect cannot be evaluated in the viability assays performed in vitro and could
lead to an underestimation of the compounds’ potency. Further, the repeated administration of F397
and F421 followed in vivo instead of the single dosage used in vitro can be an additional explanation.
Indeed, repeated and lower doses of anti-tumor agents have been reported to be more effective than
one single higher dosage against chemoresistant tumors [54]. This could also be the case of F397
and F421 against A549/DX tumors. Notably, the reduction of cell proliferation in vitro (i.e., 50%) is
similar to the extent of tumor decreases observed in vivo, indicating a good correlation between the
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two experimental settings. It is also worth noting that the treatment was not toxic for liver, heart, and
kidney compared with the control, as shown from the hemato-chemical parameters of the animals
(Table 2).
Table 2. Hemato-chemical parameters of animals.







LDH (U/L) 6782 ± 567 6729 ± 492 7182 ± 892 7092 ± 542 7189 ± 823 6652 ± 629 7141 ± 927 6981 ± 554 7089 ± 504
AST (U/L) 76 ± 32 81 ± 24 82 ± 37 91 ± 34 74 ± 34 98 ± 82 101 ± 33 72 ± 32 78 ± 38
ALT (U/L) 32 ± 10 37 ± 108 33 ± 13 41 ± 9 33 ± 10 32 ± 9 41 ± 7 40 ± 11 41 ± 8





















CPK (U/L) 298 ± 73 324 ± 72 321 ± 72 259 ± 98 301 ± 75 278 ± 65 334 ± 81 298 ± 63 292 ± 77
Balb/C mice (n = 8 animals/group) were treated as described. Blood was collected immediately after euthanasia
and analyzed for lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (AP), creatinine, and creatine phosphokinase (CPK). Data are presented as means ± SD.
* p < 0.05: vs. ctrl group.
3. Experimental Section
3.1. Materials
Compounds F397, F421, and F400 were obtained according to the previously reported
procedures [27,42,43]. Cell culture reagents were purchased from Celbio s.r.l. (Milano, Italy).
CulturePlate 96/well plates were purchased from PerkinElmer Life Science; Calcein-AM were obtained
from Sigma-Aldrich (Milan, Italy).
3.2. Cell Cultures
MDCK and MDCK-MRP1 cells were a gift of Prof. P. Borst, NKI-AVL Institute, Amsterdam, The
Netherlands. The MDCK cells were grown in DMEM high glucose supplemented with a 10% fetal
bovine serum, 2 mM glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin in a humidified
incubator at 37 ◦C with a 5% CO2 atmosphere.
3.3. Cancer Cell Lines
Human colon cancer HT29 cells and their doxorubicin-resistant counterpart HT29/DX, human
non-small cell lung cancer A549 cells and their doxorubicin-resistant counterpart A549/DX, and human
breast cancer MCF7, SKBR3, T74D and MDA-MB-231 cells were purchased from American Type Culture
Collection (ATCC; Manassas, VA, USA). The resistant sublines HT29/DX and A549/DX were obtained
by culturing cells in a medium containing increasing concentrations of doxorubicin. Every 5 passages,
the concentration of doxorubicin was increased according to this protocol: 100 pM (passages 1–5),
250 pM (passages 6–10), 500 pM (passages 11–15), 1 nM (passages 16–20), 25 nM (passages 21–25),
50 nM (passages 26–30), and 100 nM (passages 31–35). HT29/DX cells were used between passages 32
and 35, and were maintained in a medium with 100 nM doxorubicin, added three times/week, 6 h
after cell seeding. A549/DX cells were used between passages 26 and 30, and were maintained in a
medium with 50 nM doxorubicin, added three times/week, 6 h after cell seeding. In these experimental
conditions, both cell lines displayed cross-resistance to different drugs, including platinum salts [44,45].
HT29, HT29/DX, MCF7, SKBR3, T74D, and MDA-MB-231 cells were cultured in an RPMI-1640 medium,
and A549 and A549/DX cells were cultured in a HAM-F12 medium, containing a 10% fetal bovine
serum and 1% penicillin-streptomycin, in a humidified atmosphere at 37◦C. All cells were used before
passage 10.
3.4. Calcein-AM Experiments
These experiments were carried out as described by Riganti et al., with minor modifications [55].
Each cell line (30,000 cells per well) was seeded into a black CulturePlate 96/well plate with a 100 µL
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medium and allowed to become confluent overnight. The 100 µL of test compounds was solubilized in
a culture medium and added to monolayers, with final concentrations ranging from 0.1 to 100 µM. The
96/well plates were incubated at 37 ◦C for 30 min. Calcein-AM was added in 100 µL of phosphate
buffered saline (PBS) to yield a final concentration of 2.5 µM, and then the plates were incubated for
30 min. Each well was washed 3 times with ice-cold PBS. Saline buffer was added to each well and the
plates were read with the Victor3 plate reader (PerkinElmer) at excitation and emission wavelengths
of 485 and 535 nm, respectively. In these experimental conditions, the Calcein cell accumulation in
the absence and in the presence of the tested compounds was evaluated and the fluorescence basal
level was estimated with the untreated cells. In treated wells, the increase in fluorescence with respect
to the basal level was measured. EC50 values were determined by fitting the fluorescence increase
percentage vs. log(dose).
3.5. Antiproliferative Assay
The determination of cell growth was performed using an MTT assay at 24 or 72 h [55]. On
day 1, 10,000 cells/well were seeded into 96-well plates in a volume of 100 µL. On day 2, the drugs
concentrations (0.1, 1, 10, 25 µM) were added. In all the experiments, the various drug solvents
(ethanol, DMSO) were added in each control to evaluate a possible solvent cytotoxicity. After the
established incubation time with drugs, 10 µL MTT (0.5 mg/mL) was added to each well, and after 3 h
incubation at 37◦C, the supernatant was removed. The formazan crystals were solubilized using 100 µL
of DMSO and the absorbance values at 570 and 630 nm were determined on the microplate reader
Victor 3 from PerkinElmer Life Sciences. The absorbance of the untreated cells was considered equal to
100% cell viability; the viability of cells measured in each experimental condition was expressed as a
percentage of viable cells in the considered condition vs. the viability of the untreated cells.
3.6. Immunoblotting
Cells were rinsed with a boiling 0.5 mL lysis buffer (10 mM Tris, 100 mM NaCl, 20 mM KH2PO4,
30 mM EDTA, 1 mM EGTA, 250 mM sucrose; pH 7.5). After sonication, 1 mM Na3VO4, 1 mM NaF,
10 mM dithiothreitol, and the inhibitor cocktail set III (100 mM 4-(2-aminoethyl)benzenesulfonyl
fluoride, 80 mM aprotinin, 5 mM bestatin, 1.5 mM E-64, 2 mM leupeptin, 1 mM pepstatin; Calbiochem,
San Diego, CA, USA) were added and cell lysates were centrifuged at 13,000× g for 15 min. Then, 50 µg
cell proteins were separated by SDS-PAGE and probed with an anti-MRP1/ABCC1 (IU2H10, Abcam,
Cambridge, UK) and anti-actin (A2066, Sigma Chemical Co.) antibody, used as the control of equal
loading. Immunoblot quantitation (band density ratio MRP1/actin) was performed using the ImageJ
software (https://imagej.nih.gov/ij/).
3.7. Glutathione Measurement
Cells were washed with PBS and 600 µL 0.01 N HCl was added. After gentle scraping, cells were
frozen/thawed twice and proteins were precipitated by adding 120 µL of 6.5% w/v 5-sulfosalicylic acid
to 480 µL of lysate. Each sample was placed in ice for 1 h and centrifuged for 15 min at 13,000× g (4 ◦C).
The protein content was measured with a BAC Kit (Sigma Chemicals. Co), as per the manufacturer’s
instruction. Total glutathione was measured in 20 µL of the cell lysate or supernatant with the following
reaction mix: 20 µL of stock buffer (143 mM NaH2PO4 and 63 mM EDTA, pH 7.4), 200 µL of daily
reagent (10 mM 5,5’dithiobis-2-nitrobenzoic acid and 2 mM NADPH in stock buffer), and 40 µL of
glutathione reductase (8.5 U/mL). The content of the oxidized glutathione (GSSG) was obtained after
the derivatization of GSH with 2-vinylpyridine (2VP): 10 µL of 2VP was added to 200 µL of cell lysate
or culture supernatant and the mixture was shaken at room temperature for 1 h. Glutathione was then
measured in 40 µL of the sample as described. The reaction was followed kinetically for 5 min using a
Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA), measuring
the absorbance at 415 nm. Each measurement was made in triplicate and results were expressed as
nmol of glutathione/min/mg cellular protein, according to a titration curve set up with serial dilutions
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(10 µM–0.1 nM) of 1:1 GSH/GSSG mix. For each sample, GSH was obtained by subtracting the GSSG
from the total glutathione.
3.8. Total Reactive Oxygen Species (ROS) Measurement
Here, 1 × 106 whole cells were re-suspended in a final volume of 0.5 mL PBS and
incubated for 30 min at 37 ◦C with 5 µM of the fluorescent probe 5-(and-6)-chloromethyl-2’,7’-
dichlorodihydro-fluorescein diacetate-acetoxymethyl ester (DCFDA-AM, Sigma Chemicals Co.) in
the dark. Cells were then centrifuged at 13,000× g at 37 ◦C and re-suspended in 0.5 mL PBS. The
fluorescence of each sample, considered as the index of ROS levels, was read at 492 (λ excitation) and
517 nm (λ emission) using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments). The
results were expressed as nmol total ROS/mg cell proteins. A preliminary titration curve was set up by
incubating the cells for 1 h with the cells treated with serial dilutions (10–0.01 nM) of the pro-oxidant
agent menadione.
3.9. Mitochondrial ROS Measurement
Here, 1 × 106 cells were re-suspended in a final volume of 0.5 mL PBS and incubated for 30 min at
37 ◦C with 5 µM of the fluorescent probe MitoSOX Red (Invitrogen Life Technology, Milano, Italy)
in the dark. Cells were then centrifuged at 13,000× g at 37 ◦C and re-suspended in 0.5 mL PBS. The
fluorescence of each sample, considered as the index of ROS levels, was read at 510 (λ excitation) and
580 nm (λ emission) using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments). The
results were expressed as nmol mitochondrial ROS/mg cell proteins. A preliminary titration curve was
set up by incubating the cells for 1 h with the cells treated with serial dilutions (10–0.01 nM) of the
pro-oxidant agent menadione.
3.10. MRP1 Activity
Cells were washed with Ringer’s solution (148.7 mM NaCl, 2.55 mM K2HPO4, 0.45 mM KH2PO4,
1.2 mM MgSO4; pH 7.4), lysed on crushed ice with lysis buffer (10 mM Hepes/Tris, 5 mM EDTA, 5 mM
EGTA, 2 mM dithiothreitol; pH 7.4) supplemented with 2 mM PMSF, 1 mmol/L aprotinin, 10 µg/mL
pepstatin, and 10 µg/mL leupeptin, and subjected to nitrogen cavitation at 1200 psi for 20 min. Samples
were centrifuged at 300× g for 10 min, overlaid on a sucrose cushion (10 mM Tris/HCl, 35% w/v sucrose,
1 mM EDTA; pH 7.5) and centrifuged at 14,000× g for 10 min. The interface was collected, re-suspended
in the centrifugation buffer (10 mM Tris/HCl, 250 mM sucrose; pH 7.5) and subjected to a third
centrifugation at 100,000× g for 45 min. The vesicle pellet was re-suspended in a 0.5 mL centrifugation
buffer and used for the protein quantification using the BCA kit (Sigma-Merck). Then, 100 µg of the
proteins were immuno-precipitated in 100 µL of the centrifugation buffer overnight at 4 ◦C with an
anti-MRP1 antibody (diluted 1:50, Abcam, Cambridge, MA), using 25 µL pure proteome beads A/G
(Merck/Millipore, Burlington, MA, USA), and then re-suspended in 50 µL of the centrifugation buffer.
Samples were incubated for 30 min at 37 ◦C with 50 µL of the reaction mix (25 mM Tris/HCl, 3 mM
ATP, 50 mM KCl, 2.5 mM MgSO4, 3 mM dithiothreitol, 0.5 mM EGTA, 2 mM ouabain, 3 mM NaN3;
pH 7.0). The reaction was stopped by adding 0.2 mL ice-cold stopping buffer (0.2% w/v ammonium
molybdate, 1.3% v/v H2SO4, 0.9% w/v SDS, 2.3% w/v trichloroacetic acid, 1% w/v ascorbic acid). After
a 30-min incubation at room temperature, the absorbance of the phosphate hydrolyzed from ATP
was measured at 620 nm, using a Synergy HT Multi-Mode Microplate Reader (Bio-Tek Instruments).
The absorbance was converted into µmol hydrolyzed phosphate/min/mg proteins, according to the
titration curve previously prepared with serial dilutions (100–0.1 nM) of NaHPO4.
3.11. In Vivo Tumor Growth
Here, 1 × 106 A549/DX cells were mixed with 100 µl Matrigel implanted in 6-week-old female
nu/nu BALB/C mice (Charles River Laboratories Italia, Calco, Italy), housed (5 per cage) under 12 h
light/dark cycle, with food and drinking provided ad libitum. Tumor growth was measured daily by
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caliper, according to the equation (LxW2)/2, where L = tumor length and W = tumor width. When the
tumor reached the volume of 50 mm3, mice (n = 8/group) were randomized and treated as reported
in the following groups, treated on day 1, 7, and 14 after randomization: (1) vehicle group (ctrl),
treated intraperitoneally (i.p.) with 100 µL saline solution; (2) cis-Pt group, treated i.p. with 50 mg/kg
cis-Pt, dissolved in 100 µL water/10% DMSO solution, according to Kopecka et al., 2015 [53]; (3) F397
group, treated i.p. with 750 nmoles of the compound, dissolved in 100 µL water/10% DMSO solution,
corresponding to the maximum tolerated dose (not shown and Table 2); (4) F421 group, treated i.p.
with 750 nmoles of the compound, dissolved in 100 µL water/10% DMSO solution i.p, corresponding
to the maximum tolerated dose (not shown and Table 2); (5) cis-Pt/F397 group, treated i.p. with
50 mg/kg Cis-Pt and 750 nmoles of F397; (6) cis-Pt/F421 group, treated i.p. with 50 mg/kg cis-Pt and
750 nmoles of F421; (7) MK571 group, treated i.p. with 3 mg/kg MK571 dissolved in 100 µL water/10%
DMSO solution, according to Jones et al., 1989 [56]; (8) MK571/F397 group, treated i.p. with 3 mg/kg
MK571 and and 750 nmoles of F397; (9) MK571/F421 group, treated i.p. with 3 mg/kg MK571 and
750 nmoles of F421. Tumor volumes were monitored daily. Animals were euthanized at day 21
after randomization with zolazepam (0.2 mL/kg) and xylazine (16 mg/kg). Lactate dehydrogenase
(LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP),
creatinine, and creatine phosphokinase (CPK) were measured on blood samples collected immediately
after euthanasia, using commercially available kits from Beckman Coulter Inc. (Beckman Coulter,
Miami, FL, USA).
The animal care and experimental procedures were approved by the Bio-Ethical Committee of the
Italian Ministry of Health (#122/2015-PR).
3.12. Statistical Analysis
All data in the text and figures are provided as means ± SD. The results were analyzed by a
Student’s t-test and ANOVA test, using Graph-Pad Prism (Graph-Pad software, San Diego, CA, USA).
p < 0.05 was considered significant. The investigators responsible for the data analysis were unaware
of the experimental conditions analyzed.
4. Conclusions
CS, that is, a sort of synthetic lethality according to which resistant tumor cells are selectively
killed (rather than their wild type counterparts), appears as a promising therapeutic approach for
the treatment of resistant tumors. In this context, MDR pump modulators may be endowed with CS
properties. Besides the deeply explored P-gp-mediated CS, the less explored MRP1-mediated CS has an
important role. With the aim of identifying promising MRP1 modulators as CS inducers, we screened
a library of sigma-2 receptor ligands which were previously identified as P-gp-mediated CS inducers.
Three compounds, F397, F400 and F421, that modulated MRP1 and displayed cytotoxicity in a number
of cell lines, exerted a more potent cytotoxicity in the MRP1 overexpressing cells (MDCK/MRP1
and A549/DX) compared with the wild type counterparts, thus showing important CS properties.
All the three compounds were found to alter the GSH/GSSG ratio in the cell lines studied, and
to increase the mitochondrial ROS. The three compounds, that were able to exert cytotoxicity by
themselves, potently synergized with cis-Pt, re-activating this “traditional” antitumor drug in cells
refractory to the drug because of the MRP1 expression. These in vitro results were translated in the
corresponding in vivo model of cis-Pt-resistant A549/DX xenografts, where the co-administration of
the MRP1-mediated sensitizers F397 and F421 with cis-Pt greatly reduced tumor growth, with no signs
of toxicity. Importantly, both in vitro and in vivo, the activity of these sensitizers was demonstrated
to be mediated by the interaction with MRP1. Overall, we demonstrated that MRP1-mediated CS
is a promising approach for the treatment of resistant tumors such as the non-small cell lung tumor,
whose bad prognosis urgently requires novel therapeutic approaches. The results herein obtained
make these classes of compounds worthy to be further investigated for other MRP1 overexpressing
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resistant tumors, while F397, F400, and F421 may be considered as first in class for the development of
novel MRP1-mediated collateral sensitizers.
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PBS Phosphate Buffered Saline
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SR selectivity ratio
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